Celgene invests in startup that measures residual cancer cells to test a drug’s efficacy
Celgene just made an equity investment Bay Area-based Sequenta, a biotech that’s developing a minimal residual disease test for blood cancer. The startup’s ClonoSight platform senses the remaining cancerous cells in a person’s blood stream after they’ve received radiation, surgery or chemotherapy – indicating whether or not a treatment has been successful, the company said. It […]